NCT02067299View on ClinicalTrials.gov

A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Depressive Disorder, Major
Interventions
DRUG

JNJ-42847922

Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.

OTHER

Placebo

Participants will receive placebo orally on Day 1 of the appropriate treatment periods.

Trial Locations (2)

Unknown

Berlin

Leiden

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02067299 - A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants | Biotech Hunter | Biotech Hunter